Delta Sleep-Inducing Peptide (DSIP)
Neuropeptide
Also known as: DSIP, Delta Sleep-Inducing Peptide
Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.
Mean half-life ~4.0 +/- 0.7 min in dogs (IV bolus, EIA assay); also 2.9 min in one monkey and 2.0 +/- 0.54 min in rats (Kato et al., Neuroendocrinology 1984, PMID 6379493). No human plasma half-life located; a human insomnia trial (PMID 1299794) used 25 nmol/kg IV but reported no plasma half-life.
Model a dosing schedule →No established human dosing regimen found in PubMed/PMC. The only human trial located (PMID 1299794) dosed 25 nmol/kg IV (a molar research dose, not a standardized mcg protocol) and found effects 'not likely to be of major therapeutic benefit.'
Small, old literature (1980s-90s) from European/Japanese groups plus a Russian-lineage citation network. The one human double-blind RCT (n=16) found weak, inconsistent effects and concluded no major therapeutic benefit. Plasma half-life is animal-only (dog/monkey/rat), not measured in humans. Not replicated in modern trials. Sequence and MW 848.8 Da confirmed on PubChem (CID 68816).
No robust human safety data beyond one small 1990s double-blind IV trial (n=16) that found no clear benefit and did not report a systematic adverse-event profile. No modern pharmacovigilance or dose-ranging safety data exists. Absence of reported harm in this tiny, old literature is not evidence of safety.
- Development of an enzyme immunoassay for DSIP and its use in the determination of the metabolic clearance rate of DSIP administered to dogs · pubmed
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study · pubmed
- PubChem Compound Summary CID 68816, Delta Sleep-Inducing Peptide (MW 848.8) · other